Biopharma giant MSD says it stands ready to pursue new approaches to advance public health in China after its GARDASIL ...

In vaccines, sales of HPV vaccines — Gardasil and Gardasil 9 ... Merck’s pneumococcal 15-valent conjugate vaccine, were $161 million, down 9%, primarily due to lower demand in the United ...

Rising competitive pressure on the diabetes franchise and persistent challenges for its human papillomavirus vaccine, Gardasil in China ... Merck’s new 21-valent pneumococcal conjugate vaccine ...

Apart from this franchise, its lead clinical candidate is VAX-24, a 24-valent pneumococcal conjugate ... MRK’s leading HPV vaccine, GARDASIL 9, faced challenges internationally due to inventory ...

with the 9-valent vaccine following closely at 31.1%. The HPV vaccine’s annual response rate has significantly and cumulatively increased over time (Table 2). Initially dominated by the quadrivalent ...

According to Judge Kenneth Bell, there is a lack of evidence to conclude that Merck willingly misrepresented the safety of ...

New facility will manufacture HPV vaccines Gardasil and Gardasil 9. Merck plans to invest $8 billion more in U.S. by 2028. A ...

Gardasil and Gardasil 9 are together Merck's second best-selling product, with global sales of $8.58 billion in 2024. U.S. patent protection expires in 2028. The U.S. Centers for Disease Control ...